Makind Pharma delivered robust financial performance in Q1 FY27, with consolidated net profit attributable to equity holders rising 29.1% year-on-year to ₹574.09 crore for the quarter ended June 30, 2026. According to reports from CNBC TV18, this compares favorably with the ₹444.62 crore net profit recorded in the corresponding quarter of the previous financial year. The significant profit growth demonstrates the company's operational efficiency and market positioning during the April-June period. Basic earnings per share rose 29.6% to ₹13.76 from ₹10.62, reflecting the strong bottom-line performance. Profit before tax also surged 42% to ₹769 crore from ₹540 crore in Q1 FY26, indicating robust operational performance across all segments.
The pharmaceutical company's consolidated revenue from operations increased 12.9% to ₹4,030.59 crore in Q1 FY27, up from ₹3,570.35 crore in the year-ago period. As reported by CNBC TV18, this revenue growth reflects the company's ability to expand its market presence and product portfolio. Operating performance also improved significantly, with EBITDA increasing 25% year-on-year to ₹1,060 crore from ₹850 crore, while EBITDA margin expanded to 26.2% from 23.7% a year earlier. According to latest reports from TradingView News, EBITDA margin further improved to 26.3% with a 250 basis points expansion, demonstrating the company's enhanced operational efficiency and cost management capabilities during the quarter. Gross margins also improved by 230 bps to 72.8%, while profit after tax (PAT) margins rose by 170 bps to 14.2%, indicating successful cost management and favorable product mix shift towards higher-margin chronic therapies.
According to CNBC TV18, Vice Chairman and Managing Director Rajeev Juneja highlighted that the company's overall domestic business, excluding consumer healthcare, grew 11% during the quarter. The domestic business was led by strong performance in chronic therapies, with the chronic portfolio growing 15.8%, including 19.4% growth in the cardiac segment and 12.7% growth in anti-diabetes therapies. The company also reported growth recovery in its acute business, driven by the gastro, VMN and gynaecology segments, along with strong double-digit growth in the BSV domestic specialty business. The over-the-counter (OTC) business grew around 4% during the quarter, while the international business recorded 29% year-on-year growth. Latest reports confirm that both domestic and export businesses posted double-digit growth, indicating strong performance across all key segments.
The company demonstrated strong brand-level performance across key therapeutic areas, outperforming the industry prescription market (IPM) in key areas, including respiratory chronic (1.3x IPM growth) and cardiac (1.1x IPM growth). Specific brand performances included 21% growth in the Telmikind family, 30-31% growth in Lipirose and Statpure, and 29% growth in the Glizid brand family. The domestic business (excluding Consumer Healthcare) grew to ₹3,180 crore, led by double-digit growth in the Mankind domestic business. Despite softer growth, the company gained market share in key brands, including Manforce, Prega News and Gas-O-Fast. The contribution of modern trade and e-commerce increased to 15% in the first quarter from 11% a year ago, supported by 38% growth. Secondary sales of Gas-O-Fast and Ova News grew 10% and 36% year-on-year, respectively, indicating strong digital channel performance and market penetration.
The company's international business reported 29% revenue growth during the quarter, with revenue from international business increasing by 29% YoY to ₹605 crore in Q1FY27. According to CNBC TV18, the board approved several strategic initiatives during the quarter, including a corporate guarantee of up to ₹150 crore in favour of banks for credit facilities availed or proposed to be availed by Bharat Serums and Vaccines Limited, and the sale of Mankind Pharma's entire stake in Broadway Hospitality Services Private Limited for ₹49 crore in cash. Management indicated that disciplined execution and strengthening business fundamentals resulted in improvements across key operating and financial metrics during the quarter. Additionally, the company's net debt reduced to ₹3,377 crore, with the net debt-to-adjusted EBITDA ratio improving to 0.9x from 1.1x in FY26, signaling stronger balance sheet health. The Consumer Healthcare Business recorded revenue of ₹246 crore (up 4% YoY), partly impacted by base effect of discontinued cash and carry business.
